Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00521053 · ClinicalTrials.gov registry record · Phase 2
Phase 2 Study of Intralesional PV-10 for Metastatic Melanoma
A Phase 2 study, sponsored by Provectus Pharmaceuticals.
- Completed
- Registry status
- Phase 2
- Development phase
- 80
- Enrollment target
NCT00521053 is a Phase 2 study that has completed, run by Provectus Pharmaceuticals. The registered enrollment target is 80 participants.
The verdict
NCT00521053, a Phase 2 study, has completed, sponsored by Provectus Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 80 participants
- Enrollment target
Study Summary
The primary objective of this study is to investigate the effectiveness of intralesional (IL) PV-10 for locoregional treatment of metastatic melanoma. This study will also include assessment of response in untreated bystander lesions following intralesional injection of PV-10 into targeted lesions. Additional objectives are to determine the safety profile of PV-10 following intralesional injection, and assess the pharmacokinetic profile of PV-10 in the bloodstream following intralesional injection.
Interventions
- DRUG PV-10 (10% rose bengal disodium)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 80 participants |
| Start Date | 2007-09 |
| Est. Completion | 2012-06 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00521053
The ClinicalTrials.gov registry entry for NCT00521053 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 80 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Provectus Pharmaceuticals, which has 6 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which PV-10 (10% rose bengal disodium) is the first listed.
NCT00521053 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00521053 about?
NCT00521053 is a clinical study titled "Phase 2 Study of Intralesional PV-10 for Metastatic Melanoma". The primary objective of this study is to investigate the effectiveness of intralesional (IL) PV-10 for locoregional treatment of metastatic melanoma. This study will also include assessment of response in untreated bystander lesions following intralesional injection of PV-10 into targeted lesions. ...
What is the current status of trial NCT00521053?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 80 participants. The study started on 2007-09. Estimated completion is 2012-06.
What interventions are being tested in trial NCT00521053?
The interventions under investigation include: PV-10 (10% rose bengal disodium) (DRUG).
Who is sponsoring clinical trial NCT00521053?
This trial is sponsored by Provectus Pharmaceuticals, which has 6 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.